Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.
Identifieur interne : 000054 ( Main/Exploration ); précédent : 000053; suivant : 000055Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.
Auteurs : Nuriye Ezgi Bektur Aykanat [Turquie] ; Sedat Kacar [Turquie] ; Serife Karakaya [Turquie] ; Varol Sahinturk [Turquie]Source :
- Pharmacological reports : PR [ 1734-1140 ] ; 2020.
Descripteurs français
- KwdFr :
- Antinéoplasiques d'origine végétale (administration et posologie), Antinéoplasiques d'origine végétale (pharmacologie), Apoptose (effets des médicaments et des substances chimiques), Carcinome hépatocellulaire (anatomopathologie), Carcinome hépatocellulaire (traitement médicamenteux), Cellules HepG2 (MeSH), Humains (MeSH), Mouvement cellulaire (effets des médicaments et des substances chimiques), Prolifération cellulaire (effets des médicaments et des substances chimiques), Protéines de tissu nerveux (génétique), Protéines et peptides de signalisation intercellulaire (génétique), Relation dose-effet des médicaments (MeSH), Récepteurs immunologiques (génétique), Régulation négative (effets des médicaments et des substances chimiques), Silymarine (administration et posologie), Silymarine (pharmacologie), Transduction du signal (effets des médicaments et des substances chimiques), Tumeurs du foie (anatomopathologie), Tumeurs du foie (traitement médicamenteux), Évolution de la maladie (MeSH).
- MESH :
- administration et posologie : Antinéoplasiques d'origine végétale, Silymarine.
- anatomopathologie : Carcinome hépatocellulaire, Tumeurs du foie.
- effets des médicaments et des substances chimiques : Apoptose, Mouvement cellulaire, Prolifération cellulaire, Régulation négative, Transduction du signal.
- génétique : Protéines de tissu nerveux, Protéines et peptides de signalisation intercellulaire, Récepteurs immunologiques.
- pharmacologie : Antinéoplasiques d'origine végétale, Silymarine.
- traitement médicamenteux : Carcinome hépatocellulaire, Tumeurs du foie.
- Cellules HepG2, Humains, Relation dose-effet des médicaments, Évolution de la maladie.
English descriptors
- KwdEn :
- Antineoplastic Agents, Phytogenic (administration & dosage), Antineoplastic Agents, Phytogenic (pharmacology), Apoptosis (drug effects), Carcinoma, Hepatocellular (drug therapy), Carcinoma, Hepatocellular (pathology), Cell Movement (drug effects), Cell Proliferation (drug effects), Disease Progression (MeSH), Dose-Response Relationship, Drug (MeSH), Down-Regulation (drug effects), Hep G2 Cells (MeSH), Humans (MeSH), Intercellular Signaling Peptides and Proteins (genetics), Liver Neoplasms (drug therapy), Liver Neoplasms (pathology), Nerve Tissue Proteins (genetics), Receptors, Immunologic (genetics), Signal Transduction (drug effects), Silymarin (administration & dosage), Silymarin (pharmacology).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Phytogenic, Silymarin.
- chemical , genetics : Intercellular Signaling Peptides and Proteins, Nerve Tissue Proteins, Receptors, Immunologic.
- chemical , pharmacology : Antineoplastic Agents, Phytogenic, Silymarin.
- drug effects : Apoptosis, Cell Movement, Cell Proliferation, Down-Regulation, Signal Transduction.
- drug therapy : Carcinoma, Hepatocellular, Liver Neoplasms.
- pathology : Carcinoma, Hepatocellular, Liver Neoplasms.
- Disease Progression, Dose-Response Relationship, Drug, Hep G2 Cells, Humans.
Abstract
BACKGROUND
14 million people are diagnosed with new cancer and approximately 8 million people die from cancer every year. Hepatocellular carcinoma is the most common type of liver cancer and covers almost 5-6% of cancer deaths worldwide. Silybum marianum, a plant that contains silymarin, has been used traditionally in the treatment of liver diseases for centuries. The antioxidant, anti-inflammatory and anti-fibrotic anti-cancer properties of silymarin have been demonstrated in several studies in vivo and in vitro. The Slit/Robo signaling pathway plays a role in many processes such as neurogenesis, angiogenesis, cell proliferation, cell movement, cancer progression, cell invasion, migration and metastasis. In this study, we aimed to investigate the effects of silymarin on HepG2 Hepatocellular carcinoma cells on Slit-2/Robo-1 signaling pathway and CXCR-4 which plays a role in the metastasis process.
METHODS
HepG2 Hepatocellular carcinoma cells were used in the study. Different doses of silymarin's effect on HepG2 cells were observed by hematoxylin and eosin staining. Immunoblotting techniques were used to test the expression of Slit-2/Robo-1 and CXCR4 protein level. Immunocytochemistry was used to visualize the localization of Slit-2/Robo-1 and CXCR4 protein within the cells.
RESULTS
Silymarin caused apoptosis in HepG2 cells, decreased the level of CXCR-4 protein dose-dependently, and decreased the Slit-2/Robo-1 protein level at low doses and increased it at high doses.
CONCLUSIONS
Silymarin doses showed anti-carcinogenic, anti-metastatic and apoptotic effects in a dose-dependent manner on HepG2 cells through the Slit-2/Robo-1 pathway.
DOI: 10.1007/s43440-019-00040-x
PubMed: 32016841
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.</title><author><name sortKey="Bektur Aykanat, Nuriye Ezgi" sort="Bektur Aykanat, Nuriye Ezgi" uniqKey="Bektur Aykanat N" first="Nuriye Ezgi" last="Bektur Aykanat">Nuriye Ezgi Bektur Aykanat</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey. nebektur@ogu.edu.tr.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author><author><name sortKey="Kacar, Sedat" sort="Kacar, Sedat" uniqKey="Kacar S" first="Sedat" last="Kacar">Sedat Kacar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author><author><name sortKey="Karakaya, Serife" sort="Karakaya, Serife" uniqKey="Karakaya S" first="Serife" last="Karakaya">Serife Karakaya</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author><author><name sortKey="Sahinturk, Varol" sort="Sahinturk, Varol" uniqKey="Sahinturk V" first="Varol" last="Sahinturk">Varol Sahinturk</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32016841</idno><idno type="pmid">32016841</idno><idno type="doi">10.1007/s43440-019-00040-x</idno><idno type="wicri:Area/Main/Corpus">000228</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000228</idno><idno type="wicri:Area/Main/Curation">000228</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000228</idno><idno type="wicri:Area/Main/Exploration">000228</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.</title><author><name sortKey="Bektur Aykanat, Nuriye Ezgi" sort="Bektur Aykanat, Nuriye Ezgi" uniqKey="Bektur Aykanat N" first="Nuriye Ezgi" last="Bektur Aykanat">Nuriye Ezgi Bektur Aykanat</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey. nebektur@ogu.edu.tr.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author><author><name sortKey="Kacar, Sedat" sort="Kacar, Sedat" uniqKey="Kacar S" first="Sedat" last="Kacar">Sedat Kacar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author><author><name sortKey="Karakaya, Serife" sort="Karakaya, Serife" uniqKey="Karakaya S" first="Serife" last="Karakaya">Serife Karakaya</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author><author><name sortKey="Sahinturk, Varol" sort="Sahinturk, Varol" uniqKey="Sahinturk V" first="Varol" last="Sahinturk">Varol Sahinturk</name><affiliation wicri:level="1"><nlm:affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir</wicri:regionArea><wicri:noRegion>Eskisehir</wicri:noRegion></affiliation></author></analytic><series><title level="j">Pharmacological reports : PR</title><idno type="ISSN">1734-1140</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents, Phytogenic (administration & dosage)</term><term>Antineoplastic Agents, Phytogenic (pharmacology)</term><term>Apoptosis (drug effects)</term><term>Carcinoma, Hepatocellular (drug therapy)</term><term>Carcinoma, Hepatocellular (pathology)</term><term>Cell Movement (drug effects)</term><term>Cell Proliferation (drug effects)</term><term>Disease Progression (MeSH)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Down-Regulation (drug effects)</term><term>Hep G2 Cells (MeSH)</term><term>Humans (MeSH)</term><term>Intercellular Signaling Peptides and Proteins (genetics)</term><term>Liver Neoplasms (drug therapy)</term><term>Liver Neoplasms (pathology)</term><term>Nerve Tissue Proteins (genetics)</term><term>Receptors, Immunologic (genetics)</term><term>Signal Transduction (drug effects)</term><term>Silymarin (administration & dosage)</term><term>Silymarin (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques d'origine végétale (administration et posologie)</term><term>Antinéoplasiques d'origine végétale (pharmacologie)</term><term>Apoptose (effets des médicaments et des substances chimiques)</term><term>Carcinome hépatocellulaire (anatomopathologie)</term><term>Carcinome hépatocellulaire (traitement médicamenteux)</term><term>Cellules HepG2 (MeSH)</term><term>Humains (MeSH)</term><term>Mouvement cellulaire (effets des médicaments et des substances chimiques)</term><term>Prolifération cellulaire (effets des médicaments et des substances chimiques)</term><term>Protéines de tissu nerveux (génétique)</term><term>Protéines et peptides de signalisation intercellulaire (génétique)</term><term>Relation dose-effet des médicaments (MeSH)</term><term>Récepteurs immunologiques (génétique)</term><term>Régulation négative (effets des médicaments et des substances chimiques)</term><term>Silymarine (administration et posologie)</term><term>Silymarine (pharmacologie)</term><term>Transduction du signal (effets des médicaments et des substances chimiques)</term><term>Tumeurs du foie (anatomopathologie)</term><term>Tumeurs du foie (traitement médicamenteux)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Silymarin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Intercellular Signaling Peptides and Proteins</term><term>Nerve Tissue Proteins</term><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Silymarin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Silymarine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome hépatocellulaire</term><term>Tumeurs du foie</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Cell Movement</term><term>Cell Proliferation</term><term>Down-Regulation</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Hepatocellular</term><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Apoptose</term><term>Mouvement cellulaire</term><term>Prolifération cellulaire</term><term>Régulation négative</term><term>Transduction du signal</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines de tissu nerveux</term><term>Protéines et peptides de signalisation intercellulaire</term><term>Récepteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Hepatocellular</term><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Silymarine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome hépatocellulaire</term><term>Tumeurs du foie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Dose-Response Relationship, Drug</term><term>Hep G2 Cells</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules HepG2</term><term>Humains</term><term>Relation dose-effet des médicaments</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>14 million people are diagnosed with new cancer and approximately 8 million people die from cancer every year. Hepatocellular carcinoma is the most common type of liver cancer and covers almost 5-6% of cancer deaths worldwide. Silybum marianum, a plant that contains silymarin, has been used traditionally in the treatment of liver diseases for centuries. The antioxidant, anti-inflammatory and anti-fibrotic anti-cancer properties of silymarin have been demonstrated in several studies in vivo and in vitro. The Slit/Robo signaling pathway plays a role in many processes such as neurogenesis, angiogenesis, cell proliferation, cell movement, cancer progression, cell invasion, migration and metastasis. In this study, we aimed to investigate the effects of silymarin on HepG2 Hepatocellular carcinoma cells on Slit-2/Robo-1 signaling pathway and CXCR-4 which plays a role in the metastasis process.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>HepG2 Hepatocellular carcinoma cells were used in the study. Different doses of silymarin's effect on HepG2 cells were observed by hematoxylin and eosin staining. Immunoblotting techniques were used to test the expression of Slit-2/Robo-1 and CXCR4 protein level. Immunocytochemistry was used to visualize the localization of Slit-2/Robo-1 and CXCR4 protein within the cells.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Silymarin caused apoptosis in HepG2 cells, decreased the level of CXCR-4 protein dose-dependently, and decreased the Slit-2/Robo-1 protein level at low doses and increased it at high doses.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Silymarin doses showed anti-carcinogenic, anti-metastatic and apoptotic effects in a dose-dependent manner on HepG2 cells through the Slit-2/Robo-1 pathway.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32016841</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1734-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pharmacological reports : PR</Title><ISOAbbreviation>Pharmacol Rep</ISOAbbreviation></Journal><ArticleTitle>Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.</ArticleTitle><Pagination><MedlinePgn>199-207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s43440-019-00040-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">14 million people are diagnosed with new cancer and approximately 8 million people die from cancer every year. Hepatocellular carcinoma is the most common type of liver cancer and covers almost 5-6% of cancer deaths worldwide. Silybum marianum, a plant that contains silymarin, has been used traditionally in the treatment of liver diseases for centuries. The antioxidant, anti-inflammatory and anti-fibrotic anti-cancer properties of silymarin have been demonstrated in several studies in vivo and in vitro. The Slit/Robo signaling pathway plays a role in many processes such as neurogenesis, angiogenesis, cell proliferation, cell movement, cancer progression, cell invasion, migration and metastasis. In this study, we aimed to investigate the effects of silymarin on HepG2 Hepatocellular carcinoma cells on Slit-2/Robo-1 signaling pathway and CXCR-4 which plays a role in the metastasis process.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">HepG2 Hepatocellular carcinoma cells were used in the study. Different doses of silymarin's effect on HepG2 cells were observed by hematoxylin and eosin staining. Immunoblotting techniques were used to test the expression of Slit-2/Robo-1 and CXCR4 protein level. Immunocytochemistry was used to visualize the localization of Slit-2/Robo-1 and CXCR4 protein within the cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Silymarin caused apoptosis in HepG2 cells, decreased the level of CXCR-4 protein dose-dependently, and decreased the Slit-2/Robo-1 protein level at low doses and increased it at high doses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Silymarin doses showed anti-carcinogenic, anti-metastatic and apoptotic effects in a dose-dependent manner on HepG2 cells through the Slit-2/Robo-1 pathway.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bektur Aykanat</LastName><ForeName>Nuriye Ezgi</ForeName><Initials>NE</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1453-7311</Identifier><AffiliationInfo><Affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey. nebektur@ogu.edu.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacar</LastName><ForeName>Sedat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakaya</LastName><ForeName>Serife</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahinturk</LastName><ForeName>Varol</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmacol Rep</MedlineTA><NlmUniqueID>101234999</NlmUniqueID><ISSNLinking>1734-1140</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012838">Silymarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490016">roundabout protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>R6FXH13RRC</RegistryNumber><NameOfSubstance UI="C118487">Slit homolog 2 protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012838" MajorTopicYN="N">Silymarin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HepG2 cells</Keyword><Keyword MajorTopicYN="N">Hepatocarcinoma</Keyword><Keyword MajorTopicYN="N">Silymarin</Keyword><Keyword MajorTopicYN="N">Slit/Robo pathway</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32016841</ArticleId><ArticleId IdType="doi">10.1007/s43440-019-00040-x</ArticleId><ArticleId IdType="pii">10.1007/s43440-019-00040-x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Turquie</li></country></list><tree><country name="Turquie"><noRegion><name sortKey="Bektur Aykanat, Nuriye Ezgi" sort="Bektur Aykanat, Nuriye Ezgi" uniqKey="Bektur Aykanat N" first="Nuriye Ezgi" last="Bektur Aykanat">Nuriye Ezgi Bektur Aykanat</name></noRegion><name sortKey="Kacar, Sedat" sort="Kacar, Sedat" uniqKey="Kacar S" first="Sedat" last="Kacar">Sedat Kacar</name><name sortKey="Karakaya, Serife" sort="Karakaya, Serife" uniqKey="Karakaya S" first="Serife" last="Karakaya">Serife Karakaya</name><name sortKey="Sahinturk, Varol" sort="Sahinturk, Varol" uniqKey="Sahinturk V" first="Varol" last="Sahinturk">Varol Sahinturk</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000054 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000054 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32016841
|texte= Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32016841" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |